Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of late-stage and mid-stage milestones that CEO Doug Love described as setting up 2026 ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
North London Collegiate School (Singapore) has established itself as a leading British international school in Singapore - ...
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with ...
Drawing on 175 years of educational heritage from its founding school in the UK, NLCS (Singapore) nurtures individuals to be ...
One of only two Chihuly exhibitions in the world in 2026, CHIHULY at Meijer Gardens Presented by Macatawa Bank is a major exhibition of international significance. The experience spans both the ...
A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted ...
FitzRandolph Gate marks the official entrance to the university from Nassau Street, its ornate ironwork standing open since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback